Figure 3
From: Determining KLF14 tertiary structure and diagnostic significance in brain cancer progression
Expression of TPD52, PKCε, KLF14 and miRNA124 in primary and secondary groups of brain cancer. (A) Expression of TPD52 in metastatic and non-metastatic groups of brain cancer patients compared to healthy controls; (B) Expression of PKCε in metastatic and non-metastatic groups of brain cancer patients compared to healthy controls; (C) Expression of KLF14 in metastatic and non-metastatic groups of brain cancer patients compared to healthy controls; (D) Expression of miRNA 124 in metastatic and non-metastatic groups of brain cancer patients compared to healthy controls. There is an elevated expression of TPD52 and PKCε in metastatic group compared to non-metastatic group (P < 0.0001). KLF14 and miRNA124 are low in expression in metastatic group compared to non-metastatic group (P = 0.0005, P < 0.0001 respectively). Representative data were presented as mean ± SEM of triplicate experiments.). Statistical significance was measured by one-way ANOVA (****P < 0.0001 and ***P < 0.05).
